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Abstract
Background: Type 1 diabetes (T1D) is an autoimmune disease and extensive evidence has indicated a critical role
of both the innate and the adaptive arms of immune system in disease development. To date most clinical trials of
immunomodulation therapies failed to show efficacy. A number of gene expression studies of T1D have been carried out.
However, a systems analysis of the expression variations of the innate and adaptive immunity gene sets, or their co-
expression network structures in cohorts at different disease states or of different disease risks, is not available till now.
Methods: We utilized data from a large gene expression study that included transcription profiles of control peripheral
blood mononuclear cells (PBMC) exposed to plasma of 148 human subjects from four cohorts that included unrelated
healthy controls (uHC), recent onset T1D patients (RO-T1D), and healthy siblings of probands that possess high (HRS, High
Risk Sibling) or low (LRS, Low Risk Sibling) risk HLA haplotypes. Both weighted and non-weighted co-expression networks
were constructed in each cohort separately, and edge weight distribution and the activation of known protein complexes
were examined. The co-expression networks of the innate and adaptive immunity genes were further examined in more
detail through a number of network measures that included network density, Shannon entropy, h-index, and the scaling
exponent γ of degree distribution. Pathway analysis was carried out using CoGA, a tool for detecting significant network
structural changes of a gene set.
Results: Weighted network edge distribution revealed a globally weakened co-expression network induced by the RO-
T1D cohort as compared to that by the uHC, suggesting a broad spectrum loss of transcriptional coordination. The two
healthy T1D family cohorts (HRS and LRS) induced more active but heterogeneous transcription coordination globally,
and among both the innate and the adaptive immunity genes, than the uHC. This finding is consistent with our previous
report of these cohorts sharing a heightened innate inflammatory state. The spike-in of IL-1RA to RO-T1D sera improved
co-expression network strength of both the innate and the adaptive immunity genes, and enabled a global order
recovery in transcription regulation that resulted in significantly increased number of activated protein complexes.
Many of the top pathways that showed significant difference in co-expression network structures and order between
RO-T1D and uHC have strong links to T1D.
Conclusions: Network level analysis of the innate and adaptive immunity genes, and the whole genome, revealed
striking cohort-dependent differences in co-expression network structural measures, suggesting their potential in
cohort classification and disease-relevant pathway identification. The results demonstrated the advantages of systems
analysis in defining molecular signatures as well as in predicting targets in future research.
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Background
High throughput technologies that allow comprehensive
molecular profiling at multiple levels, including the mi-
croarrays and next generation sequencing, are now in
routine research use. One major challenge in systems
biology is to quantitatively define the molecular states
from such profiles and link them to the physiological or
pathological conditions under study, and hence to iden-
tify the most relevant pathways and gene sets to com-
plex traits, and to dissect underlying genetic architecture
of the latter. Along this direction, in initial studies, sets
of differentially expressed genes were used to define the
molecular “signature” of a system. Genes and proteins
work together in pathways or functional modules, and
physiological and pathological perturbations have been
shown to act through these functional units. A number
of approaches have therefore been proposed to rank
pathways or responsive network modules relevant to
phenotype variations, including gene set enrichment
analysis [1–3]. At first, most pathway analysis ap-
proaches treated genes as being independent, ignoring
their interaction relationships. The molecular state of a
pathway was often defined by taking the aggregate (or
mean) of individual gene scores [4]. More recently, a
number of new metrics have been proposed to either
bias the contribution from individual genes with their
topological positions in the network [1, 2], or to incorp-
orate directly in the definition network structural mea-
sures [5–9].
In this study, utilizing a large human transcription ex-
pression data set of Type 1 Diabetes (T1D), we investi-
gate network measures that may capture the variations
of a gene set and its associations to disease. T1D is an
autoimmune disease that results from the immune de-
struction of the insulin producing pancreatic islet β-cells.
It is one of the leading chronic diseases in children. As
in the study of many other complex diseases including
cancer [10], a number of efforts have been made to de-
velop gene expression based molecular signatures of dis-
ease, including those from us [11–13]. The goal is to
identify biomarkers that can sensitively detect and differ-
entiate disease processes, shed light on disease mecha-
nisms, and hence guide the development of new
intervention protocols and therapies. In a disease like
T1D, where the affected human tissue (pancreatic islets)
are not readily accessible (unlike cancer), peripheral
blood remains the most accessible resource and repre-
sents a practical, minimally invasive surrogate for biopsy
material [14–16]. However, the complex milieu of dis-
ease mediators, mainly cytokines, chemokines and other
immune modulators, is often too diluted in periphery
for direct detection. We have developed an alternative
approach by profiling the transcription responses of
control peripheral blood mononuclear cells (PBMC)
provoked by these mediators [11, 13, 17–19]. Both the
direct and the indirect gene expression profiling studies
repeatedly indicated an innate proinflammatory tran-
scriptional signature in T1D [11, 13–16].
The immune system consists of two arms: innate and
adaptive. Together they identify and eliminate foreign
pathogens, with the innate immune response responsible
for the first line defense and protection from invading
foreign agents, initiating and regulating the subsequent
adaptive responses, which in turn is critical to control
innate inflammation. In an autoimmune disease like
T1D, overactive immune responses fail to differentiate
the self from the non-self, and disease progression re-
quires cell types from both the innate and adaptive im-
mune systems. Indeed growing evidence suggests that
dysregulated innate and adaptive immune responses
contribute to autoimmune disorders including T1D
[20, 21]. Studies in both animal models and humans have
suggested that activation of innate immunity genes in the
islets, innate immune response signaling pathways, induc-
tion of inflammatory cytokines and activation of adaptive
immune responses, play a direct role in the pathogenesis
of T1D [22–25]. For instance, T1D patients and their fam-
ily members produce more IFNα in response to Toll-like
receptor-9 stimulation than uHC, despite having fewer
peripheral dendritic cells [26]. Gene expression studies of
T1D, including both those that directly study patients’s
blood cells and those that study the induced transcrption
profiles in surrogates, have poininted to the inovlvedment
of a number of inflammation and regulatory genes [12–
16, 27]. In our previous studies we consistently observed
that diabetics and their unaffected family members pos-
sess a heightened baseline innate inflammatory state cen-
tered on the interleukin 1 (IL-1) signaling [12, 13]. Despite
of these findings, a systems analysis of innate and adaptive
immunity genes is still not available, and how the disease
is triggered and progresses remains incompletely
understood.
Among the proinflammatory cytokines, IL-1, long
known to directly cause β-cell dysfunction and death,
has been the target for T1D therapy in several major
clinical trials including the Anti-Interleukin-1 in Diabetes
Action (AIDA) and TrialNet Canakinumab (TN-14) trials
[28, 29]. Strong preclinical evidence supporting the design
of these trials included the elevated circulating levels of IL-
1 being an effective biomarker of T1D disease course, and
the reduced incidence of T1D in animal models upon in-
hibition of IL-1 [29]. Unfortunately, like most other clinical
trials for T1D and for complex diseases in general, blockade
of IL-1 did not show efficacy in T1D despite the strong pre-
clinical evidence [28, 30]. While there are many factors that
could have confounded the outcomes of IL-1 antagonism
in these trials and should be controlled, such as the
age-dependent heterogeneity in disease course, timing of
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drug delivery, etc. [28, 31]; it is generally agreed that a
more systems approach to immunomodulation is needed
and future clinical trials should focus more on combin-
ation therapy development [28, 30–32]. A more holis-
tic view is needed of the cell types and soluble factors
involved in immune dysregulation that lead to β-cell loss
in T1D. Using global transcriptional analysis, in a recent
report we showed that correct immunomodulation by IL-
1 antagonist therapy is evident in the AIDA and TN-14
subjects, although the therapy did not produce obvious
clinical benefit [33].
In this report, using the gene expression data from
our previous studies [11, 13], we investigate the till
now unexplored co-expression network structure and
protein complex activation in three T1D family co-
horts and compared them to the uHC. We will carry
out both global investigations as well a focused and
systematic investigation of the adaptive and innate
immunity gene sets. New disease-relevant pathway
analysis will be performed using the CoGA tool [34],
which emphasizes on the variations in structural or-
ders of pathway networks.
Methods
Gene expression data
Human T1D gene expression data came from our previ-
ous studies [11–13], which is accessible through GEO
with accession number GSE52724 and GSE35725 (http://
www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE52724,
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE357
25). Details of cohort recruitment, demographics, and
experimental protocols were published previously
[11, 13]. Taken these two data sets together, we fur-
ther restrict the age at the time of study to be
between 6 and 20 years old. The data contains tran-
scription profiles of cryopreserved PBMC responding
to the sera from 148 human subjects belonging to
one of the following cohorts:
(1) 44 unrelated Healthy Controls (uHC) with no familial
history of any autoimmune/autoinflammatory disorder,
(2) 46 Recent Onset T1D (RO-T1D) patients. Blood
samples were collected after stabilization on exogenous
insulin 2–7 months after diagnosis,
(3) 28 autoantibody negative siblings of T1D patients
that are of high genetic risk (with DR3/4 haplotypes
of HLA) for T1D (HRS), and
(4) 31 autoantibody negative siblings of T1D patients of
low genetic risk (with non-DR3/4 HLA genotypes)
for T1D (LRS).
All subjects were Caucasian, with no two subjects
from a same family. All cohorts were well matched for
age and gender [12]. Additionally, the transcription
profiles induced by 38 of the RO-T1D sera spiked in
with the Interleukin-1 Receptor Antagonist (IL-1RA)
were also obtained. We previously observed elevated IL-
1A in the plasma of RO-T1D (and LRS and HRS) [11].
Both IL-1A and IL-1B bind IL-1 receptor and induce the
inflammation signal. IL-1RA is a natural inhibitor of the
pro-inflammatory effect of IL-1 that blocks activity of
both IL-1A and IL-1B and were found able to modulate
IL-1 − dependent inflammation transcription signature
induced by plasma collected from RO-T1D patients [12].
In total expression measurements are available for
21,998 genes (with unique Entrez gene IDs) after quality
filtering. In this study, to reduce noise in data, we kept
the top 15,000 genes that exhibit the highest expression
variation across all samples.
Compilation of genes important to innate and adaptive
immune responses
Genes deemed by Gene Ontology (GO, www.geneonto-
logy.org) to be involved in the following Biological Pro-
cesses (BP) were collected: innate immune responses
(GO0045087), and the regulation of (GO0045088), posi-
tive regulation of (GO0045089), and negative regulation
of (GO0045824), innate immune responses; adaptive im-
mune responses (GO0002250), and the regulation of
(GO0002819), positive regulation of (GO0002821), and
negative regulation of (GO0002820), adaptive immune
responses. The complete list of genes in these eight cat-
egories, together with their between-cohort difference
and statistical significance are summarized in Additional
file 1: Table S1 Innate & adaptive immunity genes.
Co-expression network analysis
Both weighted and non-weighted co-expression net-
works were constructed. In a weighted co-expression
network in cohort l (l = 1, 2, 3, 4), nodes were the genes,
and its edge weight matrix was given by




l is the Pearson correlation between gene i and j
in cohort l, and abs standard for “absolute value”. In a
non-weighted un-directed co-expression network, its ad-
jacency matrix Al = (Aij
l ) was defined by
Alij ¼






The diagonal elements were set to 0. In this study we
used the hard-thresholding approach, and chose r0 =
0.75, which is around 3 standard deviations above mean
abs(rij
l ) in all cohorts l, when networks were constructed
using 20 randomly selected samples in each cohort (to
remove sample size effect).
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Density of binary networks was calculated using









where N is the network size.
The degree of disorder (or the heterogeneity) in
network edge distribution was assessed using Sole
and Valverde’s formulation of Shannon entropy of
complex networks [35]. For a network with adjacency





If P(k) describes the network degree distribution, then
the average degree k = ∑all kk ⋅ P(k). It follows that the
distribution of the remaining degree [36] can be calcu-
lated from
q kð Þ ¼ k þ 1ð ÞP k þ 1ð Þ‹k› ; ð5Þ
and the Shannon entropy of this network is given by:
H qð Þ ¼ −
XN−1
k¼1q kð Þ log q kð Þð Þ ð6Þ
H(q) provides an measure of the network’s heterogen-
eity in edge distribution.
If a network is scale free, namely, its degree distribu-
tion would depend on node degree in the form of P(k) ∝
k− γ, where γ is the scaling exponent, and can be deter-
mined from the slope of a linear regression of the log-
log plot of P(k) versus k.
To further examine the structural order of co-
expression networks, we also borrowed the concept of
h-index that is widely used in scientific publication cit-
ation networks [37]. The h-index of a scientist is defined
to be x, if he/she has published at least x papers with x
or more citations each. It is designed to capture both the
productivity of a scientist, and the impact of his/her
work. It has been applied to study the relative import-
ance of biomolecules such as the emergence of patho-
gens [38]. A recent report found that in a number of
social and manmade networks, the h-index is advanta-
geous at capturing the spreading influence of nodes
when compared with node degree or coreness [39].
Protein complex activation analysis
Protein complex (PC) annotation were obtained from the
CORUM database [40] http://mips.helmholtz-muenchen.
de/genre/proj/corum/index.html). This data contained
1846 human complexes, 572 of which are involved in tran-
scription. Activation of protein complexes were assessed
through degree of co-activation of their members. First,
non-weighted co-expression networks were constructed for
each PC, by defining its adjacency matrix AP (standing for
Adjacency-Protein complex) in cohort l to be:










l are mean and standard deviation of rij
l
for all proteins pairs that do not appear simultaneously
in any known PC. Next, the largest connected compo-
nent in the co-expression network was identified. Lastly,
a PC is considered activated if the largest connected
component covered at least 50% of its members. Note
that our approach is different from protein complex en-
richment analysis proposed by others [41], in that we
emphasized on co-activation of gene pairs instead of in-
dividual genes. Also note that definition in Eq. (7) did
not take absolute value of the correlation coefficient, be-
cause members in an activated PC are expected to be
positively correlated [42].
Statistical and pathway analysis
Statistical analysis of the gene expression data was car-
ried out as previously described [11, 13]. Basic pathway
analysis were carried out using Gene Set Enrichment
Analysis (GSEA) [3]. Gene sets and pathways whose co-
expression network showed significant structural changes
between different cohorts were identified using CoGA
[34]. It identifies groups of “differentially associated” genes
between two conditions, through evaluation of the Jensen-
Shannon divergence in the graph spectral entropy of the
two corresponding co-expression networks [34].
Results
Global order decay in transcription regulation in recent
onset diabetics
Co-expression networks generated from cross-sectional
cohorts are good proxies to study the organizations and
order in transcription regulation. We first constructed
weighted co-expression networks. To eliminate potential
bias brought by the different cohort sample sizes, we
randomly sampled 20 subjects from each cohort 20
times, and determined the means and standard devia-
tions of the measures. All edges were partitioned into 20
evenly distributed bins based on their mean weight
(from the 20 random samplings). To examine the differ-
ence in cohorts and to highlight the deviations from
what would be expected in normal individuals, we con-
trasted the 3 T1D family cohorts (RO-T1D, HRS, and
LRS) against uHC, and the results were given in Fig. 1.
Overall there are less co-expression coordination in-
duced by the RO-T1D sera than that by the uHC sera,
with more number of weak edges and significantly less
number of strong edges. The number of edges with cor-
relation above 0.85 was over 30% less, and the number
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above 0.75 was ~16% less. The significance in the ob-
served difference was evaluated through sample permu-
tations, and was found to be p < 0.001. The much
weakened co-expression coordination in RO-T1D indi-
cated a broad spectrum dysregulation and lack of con-
trol in transcription. Spike-in of IL-1RA to the RO-T1D
plasma restored to a moderate degree the transcription
coordination among genes.
Siblings of T1D patients have an estimated 6% prob-
ability of developing diabetes, ~ 15-fold higher than that
of the general population. In Caucasians the majority,
>90%, of those who progress possess a high-risk DR3
and/or DR4 HLA haplotype, as compared to a carrier
frequency of approximately 40% [43]. In Fig. 1, the two
heathy T1D sibling cohorts (HRS and LRS) exhibited
opposite trend to RO-T1D cohort, with significantly ele-
vated global transcription coordination than the uHC.
We further examined the order of global transcription
regulation from the prospective of protein complex (PC)
activation. PCs are the smallest functional and structural
units of the protein-protein interaction network, carry-
ing out most of the vital and basic cellular functions. For
instance, transcription regulation by transcription factors
(TF) is most often carried out by binding of TF-formed
protein complexes to the promoter region of genes. Over
one thousand human protein complexes have been ex-
perimentally validated so far [40]. Several reports
suggested that human diseases are closely associated
with protein complexes [44, 45]. A functionally relevant
transcription induction requires designed transcription
regulations; reversely, an orderly (less chaotic or less het-
erogeneous) activation of transcription regulation likely
would result in more coordinated activation of func-
tional modules. Therefore we expect that examination of
PC activation can offer a perspective of the order in
transcription regulation.
Identification of activated protein complexes requires
different algorithms from those typically used in pathway
or gene set enrichment analyses. Pathways or gene sets
normally contain multiple modules, with positive and
negative feedback loops as well as redundancies in sig-
naling and regulation. The interactions among members
are usually sparse. We do not expect all members in a
pathway to be uniformly co-activated or co-suppressed
in a biological process of interest; and if a critical mod-
ule or signaling path is activated, we may consider the
whole pathway activated. In contrast, a protein complex
is an entity where members are physically associated
with each other and acts as one functional unit; its acti-
vation requires all its members to be co-activated.
Therefore, we expect that members of an activated pro-
tein complex to show a high positive correlation in their
expression variations (i.e., high degree of co-expression)
[42]. In our dataset, we indeed found that gene pairs
Fig. 1 The relative difference to uHC in the distribution of co-expression network’s edge weight. The RO-T1D plasma induced much weaker co-
expression networks than did plasma of the uHC cohort, with significantly less number of high weight edges. The HRS and LRS cohorts exhibited
a trend opposite to that of the RO-T1D. IL-1RA spike-in to the RO-T1D sera moderately improved the co-expression strength
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appearing in the same protein complexes showed
higher co-expression than gene pairs that are not
(Additional file 2: Figure S1).
Using the approach described in Methods, we identi-
fied activated protein complexes in each cohort, and the
numbers were summarized in Table 1. We only kept
those of size 5 (with maximally 10 network edges) or
above, smaller protein complexes have too few subunits
for meaningful co-expression assessment. The complete
list of activated PCs in all cohorts and their functional
annotations is available in Additional file 1: Table S2.
The top three functional categories shared by them are
cell cycle, metabolism and transcription. Overall the
uHC cohort activated a much higher number of PCs
than the three T1D family cohorts (19, versus 10, 1 and
4 for the RO-T1D, HRS, and LRS cohorts, respectively).
Among the PCs activated in the three T1D family co-
horts, there was also significant fewer that are involved
in transcription (Table 1, in parenthesis). The results in-
dicated a global order decay in induced transcription
regulation by the three T1D family cohorts, and hence
much fewer functional modules (i.e. PC) of the basic cel-
lular biological processes were activated. Taken Fig. 1
and Table 1 together, the findings suggested that com-
pared to the uHC, the RO-T1D induced globally weak-
ened and more disordered coordination in transcription
among genes, with fewer activated functional modules;
the two healthy T1D families induced more active, but
more heterogeneous/disorderly global gene-pair level co-
ordination, such that the higher number of co-expressed
gene pairs did not lead to activation of more functional
modules. Interestingly, the spike-in of IL-1RA to the
RO-T1D sera, though only mildly restored the global
pairwise co-expression (Fig. 1), significantly increased
number of activated PCs (26, even higher than the 19 of
the uHC, Table 1), with a similar proportion that are in-
volved in transcription to the uHC (11 out of 26, 42%,
versus 7 out of 19, 37%). The results suggested that by
spiking-in IL-1RA, we have introduced a strong regu-
latory signal into those co-cultures that seemingly
restored order.
Co-regulation analysis of genes involved in innate and
adaptive immunity
The complete list of genes in the eight GO biological
processes categories related to innate and adaptive im-
mune responses, together with their between-cohort
Fold Change (FC) and statistical significance are
summarized in Additional file 1: Table S1 Innate &
Adaptive Genes. We first examined reports of expression
changes of their member genes in existing gene expres-
sion studies.
In our first report of patient plasma induced tran-
scrption profiles in surrogates [13], we observed that the
plasma of RO-T1D triggered a partially IL-1 dependent
signature, which included induction of IL1B, CCL2,
CCL7, ICAM1 and PTGS2, relative to the plasma of
uHC. CCL2 and ICAM1 are known innate immune re-
sponse genes and IL1B is a adaptive immune response
gene, according to GO (Additional file 1: Table S1). We
found that establishment of this signature preceded both
the development of autoantibodies and clinical diagnosis
by up to 5 years [13]. Consistent with our observations,
others also reported a proinflammatory, IL-1 biased sig-
nature in cultured human islets exposed to T1D plasma
[27]. In our subsequent studies, we found that relative to
the uHC, an elevated, partially IL-1 dependent inflam-
matory state was also present in unaffected siblings of
T1D probands [12, 13]. Interestingly, among the three
T1D cohorts, the signature of the LRS was the most dis-
tinct from the uHC, and with the most robust induction
of innate inflammatory transcripts. The genes induced
included IL1B, CCL2, CCL3, CCL7, CXCL1, CXCL2,
CXCL3, CD14 and TREM1, where CCL2, CCL3, CD14,
and TREM1 are annotated by GO to be innate immune
response genes, and IL1B an adaptive immune response
gene (Additional file 1: Table S1). We also observed that
this familial inflammatory state displayed greater evi-
dence of being immunoregulated among the HRS com-
pared with the LRS. The HRS signature exhibited more
robust induction of IL-10/TGF-β dependent transcripts,
suggesting more active immunoregulatory mechanisms.
The genes induced included TGFBR2, SMAD9, SMAD5,
SKI, SKIL SMURF1, SMURF2, FCGR2B, PIAS1, CASP8,
and LGALS3, etc. Among them, PIAS1 CASP8 and
LGALS3 are involved in innate immune response
(Additional file 1: Table S1).
The studies that directly profiled gene expression vari-
ations in patient PBMC also reported many genes in the
innate and adaptive immune responses. Kaizer et al. [14]
found that PBMCs of pediatric RO-T1D exhibited an in-
nate inflammatory transcriptional profile that included
elevated IL1B, PTGS2, CXCL1, EGR2, EGR3 and
TREM1 levels, which resolved in the months after diag-
nosis. Stechova et al. examined the transcriptional pro-
files of PBMCs isolated from pediatric RO-T1D, their
healthy autoantibody-negative first-degree relatives and
uHC, and found that the most significantly altered immune
response pathway was IL-1 signaling [15]. A study by
Reynier et al. [16] that investigated gene expression profiles
of unfractionated whole blood reported an IFN-regulated
signature that was associated with pediatric RO-T1D
Table 1 Number of protein complexes activated in each cohort
(only PCs of size 5 and above were considered)
uHC RO-T1D HRS LRS RO + IL-1RA
19 (7)a 10 (1) 1 (0) 4 (1) 26 (11)
ain parenthesis are the numbers of protein complexes involved in transcription
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and their autoantibody-positive first-degree relatives.
The signature included expression of IFI27, OASL,
ISG15, IFIT3, GBP1, IFIT2, IFIT1, OAS3, STAT1,
RSAD2, IFI44A, all but IFI44 are innate immune re-
sponse genes (Additional file 1: Table S1).
In summary, a number of individual innate and adap-
tive immune response genes (collected in Additional file 1:
Table S1) showed significant differential expression in T1D.
We found that, however, conventional gene-level analysis
(heatmaps, volcano plots, etc.) were not able to reveal any
clear set-level pattern in the eight innate and adaptive im-
munity gene sets (Additional file 2: Figures S2 and S3). The
enrichment for differentially expressed genes was moderate,
with odds ratio ranged 1.25 to 1.37 for the eight GO BP cat-
egories, and dropped to around 1 when only genes of com-
parable expression levels were included (genes of known
functions, such as those in these eight GO categories, tend
to be expressed at higher levels than average genes). Indeed,
in our previous reports, none of the eight categories came
up on top in pathway analysis (see Table 3 of [13], Table 1
of [11]). Using the GSEA tool [3] we performed a focused
enrichment analysis of these eight gene sets only (thus
mostly avoiding the need of the multiple-pathway testing
correction). Only two categories were significant between
RO-T1D and uHC (Additional file 1: Table S3): innate im-
mune responses (GO0045087), and the negative regulation
of innate immune responses (GO0045824). This analysis
demonstrated the utility as well as the challenges when
using a conventional statistical and pathway analysis ap-
proach: while it is good at providing a first pass global pic-
ture, it may miss some biologically relevant pathways.
There are several reasons for this. One is the multiple-
testing correction problem when there is no prior hypoth-
esis, as one need to test all the available pathways/gene sets.
Another reason, which is often overlooked, is the fact that
the expression level and the variation of a given gene is
dependent on its ontology/function [46]. Genes occupying
important positions in interaction networks and playing
regulatory roles (e.g. those that interact with many, or influ-
ence or regulate the expression of other genes) often exhibit
smaller dynamic ranges of expression variations [47, 48]. In
fact, in our previous report we observed that the induction
of transcripts encoding proinflammatory mediators by T1D
plasma was more robust than the induction of regulatory
transcripts in the signatures of healthy controls in cross-
sectional analyses [12].
While integration with biological knowledge can help
to alleviate the multi-testing problem by focusing only
on those pathways with prior hypothesis, incorporating
consideration of interaction structure can help to ad-
dress the second challenge and improve the sensitivity of
detection of biologically-relevant pathways. In our data-
set, when we examined the co-expression network struc-
ture of genes involved in innate and adaptive immunity,
more interesting observations emerged. The edge weight
distributions of the co-expression networks were pre-
sented in Fig. 2. All T1D families show striking differ-
ences in transcription coordination from uHC.
Interestingly, transcription coordination of the innate
and adaptive genes induced by the RO-T1D showed op-
posite trend from that induced by the uHC, with the
adaptive genes following a similar trend to that of the
background genes and innate genes following an oppos-
ite trend (compare Figs. 1 and 2).
We previously observed elevated IL-1A in the plasma
of RO-T1D (and LRS and HRS) [11]. IL-1RA is a natural
inhibitor of the pro-inflammatory effect of IL-1 that
blocks activity of both IL-1A and IL-1B and we found it
able to modulate IL-1 − dependent inflammation tran-
scription signature provoked by the RO-T1D plasma
[12]. Interestingly, the introduction of IL-1RA to the
RO-T1D sera overall made the RO-T1D behave more
like the two healthy T1D family cohorts (HRS and LRS).
In our data, the expression measurements were avail-
able for 842 innate and adaptive immunity genes. Only
around one quarter of them are annotated in the
CORUM protein complex database, too few for a proper
protein complex activations analysis as we did in the
previous section.
Network structural measures of genes involved in innate
and adaptive immunity
We further constructed unweighted co-expression net-
works as defined by Eq. (2) and compared the density
and a set of structural measures (Figs. 3 and 4). In gen-
eral the co-expression networks are sparse, with density
ranging between ~0.1-1%. The relative difference to
uHC of each cohort is given in Fig. 3. Again, the global
transcriptome induced by RO-T1D exhibited lower net-
work density, indicating weakened transcription coord-
ination, while those induced by HRS and LRS showed
high global coordination. The two T1D family cohorts
HRS and LRS largely behaved similarly, except for genes
involved in positive regulation of innate or positive regu-
lation of adaptive immune responses, potentially respon-
sible for their differential disease risk. These two gene
categories are also the ones where their genes shows the
most elevated coordination in the two healthy T1D fam-
ily cohorts compared to uHC. The addition of IL-1RA
reversed the trend of RO-T1D in majority, six out of
eight, of the gene categories (Fig. 3).
In Fig. 4, the network measures are also compared
with random selected, same number of, genes in the
same cohort (dashed lines, 95% CI obtained through 500
random samplings). Note that since the innate and adap-
tive networks are of different sizes, it is not meaningful
to directly compare them; instead, we should compare
the differences to their corresponding controls. Z scores
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of the network measures (against random gene networks
of the same size) are available in Additional file 2:
Figure S4. In our previous report [12, 49], by examin-
ing the expression levels of key inflammation genes
we found that the LRS signature exhibited the most
robust induction of innate inflammatory transcripts;
and that the HRS signature exhibited more robust in-
duction of active immunoregulatory mechanisms, as
reflected by IL-10/TGF-β dependent transcripts. The
HRS, possessing high-risk HLA haplotypes, is also ex-
pected to exhibit increased likelihood of an adaptive
response and diabetes progression. Interestingly, from
Fig. 4, the LRS cohort induced the most dense co-
expression network of the innate immunity genes
while the HRS of the adaptive immunity genes. We
examined the top hubs in each co-expression intranet
(defined to be the top 5 ranked genes in terms of
network degree in the corresponding co-expression
network, Additional file 1: Table S4). There are in
total 21 hubs observed in the innate intranet in the 5
cohorts, with 5 of them shared in two or more co-
horts: FCER1G, TYROBP, DUSP6, OAS2, HERC5.
Two of them FCER1G, and TYROBP are hubs in 3
cohorts: uHC, RO-T1D, and RO + IL-1RA; DUSP6, is
a hub in both RO-T1D and LRS; and OAS2, HERC5,
are hubs in both UHC and HRS. FCER1G is also a
hub in RO-T1D adaptive intranet. The adaptive co-
expression intranets did not share any hubs. Some of
the hubs were reported previously to be active inflam-
mation or regulatory genes (IFIT3 [16], a hub in HRS
innate intranet, LGALS3 [12, 13], a hub in LRS adap-
tive intranet, Additional file 1: Table S4).
The background co-expression network landscape is
also strongly cohort dependent. Note that as we indi-
cated in methods, these cohorts were all from a same
race (Caucasian), matched for age and gender, each of a
large sample size (ranged 28–46, totaling 148 subjects).
Therefore the background difference likely is related to
their difference in disease status, and the genetic and en-
vironmental risks for disease. In all cohorts, the immune
response genes are more coordinated with each other
than background genes. In addition, the innate immunity
genes formed much denser networks than background
genes, as compared to the adaptive immunity genes, and
exhibiting the highest density in the HRS and LRS co-
horts. Whether it is the innate or the adaptive immunity
genes, their co-expression networks were the weakest in
the RO-T1D among all 5 cohorts.
The innate immunity genes showed a higher degree of
coordination in all the T1D family cohorts than was
Fig. 2 The relative difference to uHC in the distribution of co-expression network’s edge weight, for the innate and adaptive immunity genes.
Genes involved in innate immunity showed stronger co-expression in all T1D family cohorts, while genes involved in adaptive immunity, exhibited
weaker coordination in HRS. The LRS has no data in the last bin
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Fig. 4 Structural measures of co-expression networks of innate and adaptive immunity genes. Dashed lines represent the 95% confidence interval
of randomly selected gene sets of the same size
Fig. 3 The co-expression network density of the innate and adaptive genes in each T1D family cohort as compared to the uHC cohort, showing
distinct cohort difference
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observed in the uHC, with the most significant elevation
observed in the LRS cohort. This is consistent with our
observations of an elevated innate state amongst T1D
family members [12]. The RO-T1D induced the lowest
degree of immune gene coordination might be surpris-
ing at first. However, T1D results from the autoimmune
destruction of the pancreatic islet β-cells; by the time of
onset, majority of the β-cells are already destroyed, and
the autoimmune activities has passed its prime.
The results of the other network measures (entropy,
h-index, γ) for innate and adaptive immunity genes are
also summarized in Fig. 4 (second to fourth columns,
and Additional file 2: Figure S4). The Shannon entropy
reflects the heterogeneity (or lack of order) in the net-
work edges [35], i.e., in the co-expression coordination
among genes. In all cohorts both the innate and adaptive
genes showed higher entropy in their coordination (indi-
cating higher heterogeneity) than random genes (Fig. 4,
second column). This is likely contributed partially by
their much higher network density (Fig. 4, first column).
The RO-T1D induced innate immunity gene transcrip-
tion exhibited the highest elevation in entropy from the
random background genes. Putting the three T1D family
cohorts together, the results suggest that in the two
healthy cohorts the innate genes coordinate with each
other significantly more than expected by chance, and
the increased interaction did not lead to significant in-
crease in entropy suggesting strong order in transcrip-
tion regulation; in contract, the RO-T1D patients also
induced higher than expected interaction among the in-
nate genes, most of increase are heterogeneous and
chaotic, leading to much increased entropy. The cohort-
dependent entropy variation of adaptive immunity genes
is similar to that of the background genes.
The functional module (i.e. protein complex) activa-
tion analysis carried out in the previous section sug-
gested that there is global order decay in all three T1D
family cohorts. At the order of magnitude level, the two
healthy T1D cohorts (HRS and LRS) barely activated
any protein functional modules (the numbers are in sin-
gle digits, 1 & 4), in contrast to the double-digit protein
complexes activated by the other three cohorts (19, 10,
and 26 for uHC, RO-T1D, and RO + 1L1RA, respect-
ively). At bulk level, this is consistent with the much
higher entropy values of the background networks in-
duced by the HRS and LRS cohorts in contrast to the
other three cohorts.
The h-index suggested that there are more high-
impact, influential hub gene nodes in the innate or the
adaptive immunity intranet than random. The cohort
dependent variations could largely be explained by the
network density differences. The co-expression networks
showed good scale-free behavior, both for the innate or
adaptive immunity genes, as well as for the whole
transcriptome (Additional file 2: Figure S4). The results
of the scaling exponent γ were consistent with the other
network measures. In general, and as expected [35], the
lower the value of γ is, the more distributed the network
is, with higher entropy, and a higher number of hub
nodes (i.e. higher h-index).
In this study the co-expression network was con-
structed using the simple Pearson-correlation-based
adjacency matrix approach. We also investigated other
approaches including using the topological overlapping
matrix, the findings are similar (data not shown).
Pathways that showed significant difference in network
structural order between RO-T1D and uHC
In the previous sections, we have shown that the
diseases-relevant pathways/gene sets (innate and adap-
tive immune responses) exhibit significant changes in
their network structural measures, but may not be iden-
tified by the conventional pathway or gene set enrich-
ment analysis approaches. The results highlighted the
importance of a pathway analysis approach that incorpo-
rates the consideration of network measures. Using CoGA
[34], we investigated the KEGG pathways (http://www.ge
nome.jp/kegg/pathway.html) whose co-expression net-
work structure is different between RO-T1D and uHC.
CoGA compares a variety of network structural features
including the graph spectral entropy, to determine the
statistical significance of network alterations [34]. Those
with p < 0.05 are listed in Table 2. In the previous studies
of this same data set, we used more conventional pathway
analysis approaches that did not incorporate network
structure considerations (see Table 3 of [13], and Table 1
of [11]). We can see that the CoGA was able to uncover a
number of new pathways.
The top pathways are clearly associated to T1D, with
the number two being the pathway of “HSA04940: TYPE
I DIABETES MELLITUS”. Many of the genes in this
pathway (Additional file 2: Figure S5) are involved in in-
flammation or immune regulations (IL-1, IFγ, TNFα,
MHCII, etc.). The number one significant pathway is
HSA00072: SYNTHESIS AND DEGRADATION OF
KETONE BODIES (Additional file 2: Figure S5). Most
hospital admissions of T1D occur as a result of diabetic
ketoacidosis, a condition of overly high level of ketone
bodies, which is a direct consequence to a body’s lack of
insulin. Ketoacidosis predominantly occurs in those with
T1D [50]. The number three pathway The (DNA)
Mismatch repair pathway (Additional file 2: Figure S5)
has also been associated with T1D. Defects in mismatch
repair results in minisatellite and microsatellite instabil-
ity. The allelic variation in minisatellites has been associ-
ated with T1D risk [51, 52]. Many other pathways in
Table 2 have also been linked to T1D, for instance, both
mathematical modeling and laboratory studies have
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indicated that impaired phagocytosis contribute to T1D
[53, 54]. We propose that these pathways offer new in-
sights to the disease pathogenesis of T1D, and maybe
new candidate targets for intervention.
Discussion
As stated by Linus Pauling: “Life is a relationship among
molecules and not a property of any molecule.” In com-
plex systems, structure defines function. The genomes of
higher organisms devote a larger proportion of genes in
regulations, and their complexity lies in the more so-
phisticated network structures rather than number of
genes. Complex traits and diseases result from the inter-
actions of many genes within a dynamic environmental
background. Disruption of genetic network architecture
is believed to contribute to many complex diseases. In
this study, our analysis revealed striking differences in
the co-expression network structural measures suggest-
ing their potential in cohort classification, molecular
state definition, and disease-relevant pathway identifica-
tion. While the results were encouraging, they also re-
vealed many challenges in network modeling. There was
no single network measure that performed the best at
capturing the cohort-dependent difference. Recently we
have seen an increase in the appreciation of the import-
ance of network structure, and a boom of the “third gen-
eration” pathway analysis tools that incorporate the
consideration of network structure [7, 9]. However, while
a number of structural metrics have been proposed,
there is no clear winner [55]; it is still not clear how to
best characterize the functional impact of network struc-
tural variations, nor is it known whether we can depict
the molecular state of a network using one or several
numbers. Is it feasible to identify an “orthonormal basis”
to characterize the network structure? More efforts are
warranted to answer these questions.
Note that a network-based approach complement the
more conventional gene-based approach, they are not to
replace each other; rather, they can be and should be
integragted. While a gene-based approach is good at
quickly identifying genes exhibited the most significant
variations, a network-based approach is able to provide a
more systems picture, revealing what interactions be-
tween genes have changed. Given the complexity of hu-
man physiology and disease, and the current incomplete
understanding of their genetic architecture, we are
somewhat like the blind men and an elephant, using dif-
ferent approaches to obtain different perspectives. When
integrated, they together will hopefully give us a picture
that is closer to the truth. Most of the gene expression
studies in T1D till now used the gene-based approach,
and were able to identify the inovlvedment of a num-
ber of inflammation and immune regulatory genes
[12–16, 27]. In this study, through a systems network-
based approach, we showed that healthy T1D family co-
horts exhibited distinct gene coordination characteristics
from that of the unrelated healthy controls, particularly
the more active but more chaotic coordination of in-
nate immune response genes, likely have resulted
from the common genetics and/or evironmental fac-
tors shared among the T1D family members. This is
also consistent with our previous report of these co-
horts possessing a heightened innate inflammation
state based on gene-level observations [12, 13]. The
immune system is not isolated from other compo-
nents in the human body. All network structural
measures also showed clear cohort-dependent differ-
ences for randomly selected genes from the whole
transcriptome (Fig. 4), indicating global differences in
the transcription regulation landscape. If and how this
landscape difference contribute to risk for auto-
immunity? Or is it a result of the underlying defects
in immune regulation? Is it related the genetic dispos-
ition to T1D (non-DR3/4 HLA genotypes, etc.)? These
questions worth further investigation and the answer will
help us to determine the molecular and physiological state
of the body, and within the context, understanding disease
development.
Numerous single drug agent clinical trials for the major
common complex diseases have been carried out, over-
whelming majority of them failed to show benefit. In T1D
Table 2 KEGG pathways whose co-expression networks are
significantly different in structure between the RO-T1D and uHC,
as identified by CoGA




HSA00072 Synthesis and degradation
of ketone bodies
9 0.00099
HSA04940 Type I diabetes mellitus 43 0.0040
HSA03430 mismatch repair 23 0.012
HSA00604 Glycosphingolipid
biosynthesis - ganglio series
15 0.017




HSA05416 Viral myocarditis 70 0.020
HSA04142 Lysosome 120 0.022
HSA04145 Phagosome 148 0.025
HSA05140 Leishmaniasis 73 0.027
HSA05330 Allograft rejection 37 0.030
HSA03008 Ribosome biogenesis in
eukaryotes
74 0.033
HSA03030 Dna replication 36 0.038
HSA05110 Vibrio cholerae infection 54 0.042
HSA00603 Glycosphingolipid biosynthesis -
globo series
14 0.049
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none of the recent trials of IL-1 antagonism demonstrated
efficacy, despite the mounting evidence from animal
model and preclinical studies of an important role the IL-
1 signaling pathway played. The need of developing com-
bination therapies is now increasingly appreciated [31]. In
T1D it has been purported that a successful combination
therapy will need consider all major players and their in-
teractions: agents that modulate the innate and adaptive
immune systems, and agents that preserve β-cell health
and function [32]. However, implementation is not easy,
design of the right combination is a challenge, and the few
attempts of combination therapy in T1D have to date
mostly failed [32]. A systems evaluation of the transcrip-
tomic states and the definition of quantitative measures of
such states will shed light to the identification of key
agents and the design of their combinations in therapy. In
our previous report we showed that although the IL-1 an-
tagonism failed to generate positive clinical outcome in
AIDA and TN-14, from blinded analysis of expression
profiles alone, we were able to correctly call 70.2% of
AIDA and 68.9% of TN-14 subjects to their treatment
arm (treated or placebo) [33]. In the current analysis, we
showed that spike in of IL-1RA restored the order to a
moderate degree in transcription regulation globally, af-
fected the adaptive immunity gene network more than the
innate network (Fig. 4).
Conclusions
In this study, we found a significant, broad spectrum
global weakening in the transcription regulation induced
by the RO-T1D cohort plasma in surrogate PBMC, and
increased heterogeneity and loss of order in that induced
by all three T1D family cohorts. In addition all T1D fam-
ily cohorts induced more active but heterogeneous and
disorderly transcription of the innate immunity genes,
consistent with our previous report of the existence of a
heightened basal innate inflammatory state in them.
Spike-in of IL-1RA partially alleviated the dysregulation
in innate immunity genes. Whether it is co-expression
or protein interaction networks, we found that the co-
horts showed more striking difference in network struc-
tures and could be clearly discriminated, than in gene
expression measurements alone. We further employed
CoGA, a graph theory based pathway analysis tool [34],
to identify pathways exhibited network structural
changes between RO-T1D and uHC. A number of new
pathways were predicted, which, under close examin-
ation, displayed strong disease relevance and hence po-
tential of being noval targets for intervention. Our
results demonstrated both the importance of a systems
data analysis in providing insights to the genetic archi-
tecture of disease disk, as well as the challenges in such
an analysis.
Additional files
Additional file 1: Table S1. Innate & adaptive immunity genes. Table S2.
Activated protein complexes. Table S3. GSEA results of the expression
difference of innate and adaptive immunity genes between RO-T1D and
uHC. Table S4. Hub genes in co-expression networks of innate & adaptive
immunity genes. Hub genes are fined to be those whose network degrees
are in the top 5. (XLSX 484 kb)
Additional file 2: Figure S1. Genes in the same protein complexes show
higher co-expression than genes that are not. Figure S2. Expression heat-
map of the adaptive and innate immune response genes. Figure S3. Vol-
cano plots that compares the distribution of the innate and adaptive
immune response genes (red) against all genes (black), showing no obvious
deviation. Figure S4. Z-scores of the network measures presented in Fig. 4.
Solid lines: innate network; dashed lines: adaptive network. Figure S5. The
intranet of the innate and adaptive immunity genes exhibit good scale-free
behavior. Figure S6. Top 3 KEGG pathways (see Table 2) that are different
in co-expression network structure between RO-T1D and uHC, as identified
by CoGA. Color of a node indicates the expression log2FC of the corre-
sponding gene between RO-T1D and uHC. (PDF 408 kB)
Abbreviations
HRS: High risk sibling; LRS: Low risk sibling; RO: Recent onset; uHC: Unrelated
healthy control
Acknowledgements
We thank Dr. Xue Zhang for her assistance with protein complex analysis.
Funding
This work was partially supported by the Intramural Research Program of the
NIH, NHLBI; by The Juvenile Diabetes Research Foundation International
(grants 1-2008-1026, 5-2012-220, 17-2012-621, 2-SRA-2015-109-Q-R to MJH);
American Diabetes Association (grant 7-12-BS-075 to MJH); National Institutes
of Health (grants R01AI078713 to MJH, DP3DK098161 to MJH/CJG,
R01DK080100 to XW, and the National Center for Advancing Translational
Sciences, National Institutes of Health grant 8UL1TR000055); and The Children’s
Hospital of Wisconsin Foundation.
Availability of data and materials
The microarray gene expression datasets described in the manuscript were
downloaded and are available from the GEO database (GSE52724 and GSE35725).
Authors’ contributions
SG, XW, MJH designed the study. SJ and MJH prepared the data. SJ and SG
performed the statistical analysis. NW, SG, and XW performed co-expression
network analysis, YC performed the pathway analysis, all participated in
manuscript preparation. XW lead the writing of the manuscript. All authors
read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
Ethics approval was not required for this study. The two studies that generated
the data analyzed here were approved by the institutional review board of
Children’s Hospital of Wisconsin (IRB 01–15), and written informed consent was
obtained from subjects or their parents/legal guardians.
Author details
1Systems Biology Center, National Heart, Lung and Blood Institute, NIH,
Bethesda, MD 20892, USA. 2Department of Pediatrics at the Medical College
of Wisconsin and the Children’s Research Institute of the Children’s Hospital
of Wisconsin, The Max McGee National Research Center for Juvenile
Diabetes, 8701 Watertown Plank Road, Milwaukee, WI 53226, USA. 3The
Human and Molecular Genetics Center, The Medical College of Wisconsin,
8701 Watertown Plank Road, Milwaukee, WI 53226, USA. 4The Department of
Gao et al. BMC Medical Genomics  (2017) 10:7 Page 12 of 14
Physics, University of Alabama at Birmingham, 1300 University Blvd,
Birmingham, AL 35294-1170, USA.
Received: 26 January 2016 Accepted: 25 January 2017
References
1. Hung JH, Whitfield TW, Yang TH, Hu Z, Weng Z, DeLisi C. Identification of
functional modules that correlate with phenotypic difference: the influence
of network topology. Genome Biol. 2010;11:R23.
2. Thomas R, Gohlke JM, Stopper GF, Parham FM, Portier CJ. Choosing the
right path: enhancement of biologically relevant sets of genes or proteins
using pathway structure. Genome Biol. 2009;10:R44.
3. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA,
Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP. Gene set
enrichment analysis: a knowledge-based approach for interpreting genome-
wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545–50.
4. Ideker T, Ozier O, Schwikowski B, Siegel AF. Discovering regulatory and
signalling circuits in molecular interaction networks. Bioinformatics. 2002;18
Suppl 1:S233–40.
5. Carter SL, Brechbuhler CM, Griffin M, Bond AT. Gene co-expression network
topology provides a framework for molecular characterization of cellular
state. Bioinformatics. 2004;20(14):2242–50.
6. Liu CC, Chen WS, Lin CC, Liu HC, Chen HY, Yang PC, Chang PC, Chen JJ.
Topology-based cancer classification and related pathway mining using
microarray data. Nucleic Acids Res. 2006;34(14):4069–80.
7. Gao S, Wang X. TAPPA: topological analysis of pathway phenotype association.
Bioinformatics. 2007;23(22):3100–2.
8. Gao S, Jia S, Hessner MJ, Wang X. Predicting disease related subnetworks for
type 1 diabetes using a new network activity score. Omics. 2012;16(10):566–78.
9. Mitrea C, Taghavi Z, Bokanizad B, Hanoudi S, Tagett R, Donato M, Voichita C,
Draghici S. Methods and approaches in the topology-based analysis of
biological pathways. Front Physiol. 2013;4:278.
10. Chibon F. Cancer gene expression signatures - the rise and fall? Eur J Cancer.
2013;49(8):2000–9.
11. Levy H, Wang X, Kaldunski M, Jia S, Kramer J, Pavletich SJ, Reske M, Gessel T,
Yassai M, Quasney MW, Dahmer MK, Gorski J, Hessner MJ. Transcriptional
signatures as a disease-specific and predictive inflammatory biomarker for
type 1 diabetes. Genes Immun. 2012;13(8):593–604.
12. Chen YG, Cabrera SM, Jia S, Kaldunski ML, Kramer J, Cheong S, Geoffrey R,
Roethle MF, Woodliff JE, Greenbaum CJ, Wang X, Hessner MJ. Molecular
signatures differentiate immune states in Type 1 diabetes families. Diabetes.
2014;63:3960–73.
13. Wang X, Jia S, Geoffrey R, Alemzadeh R, Ghosh S, Hessner MJ. Identification
of a molecular signature in human type 1 diabetes mellitus using serum
and functional genomics. J Immunol. 2008;180(3):1929–37.
14. Kaizer EC, Glaser CL, Chaussabel D, Banchereau J, Pascual V, White PC. Gene
expression in peripheral blood mononuclear cells from children with diabetes.
J Clin Endocrinol Metab. 2007;92:3705–11.
15. Stechova K, Kolar M, Blatny R, Halbhuber Z, Vcelakova J, Hubackova M,
Petruzelkova L, Sumnik Z, Obermannova B, Pithova P, Stavikova V, Krivjanska
M, Neuwirth A, Kolouskova S, Filipp D. Healthy first-degree relatives of
patients with type 1 diabetes exhibit significant differences in basal gene
expression pattern of immunocompetent cells compared to controls:
expression pattern as predeterminant of autoimmune diabetes. Scand J
Immunol. 2012;75(2):210–9.
16. Reynier F, Pachot A, Paye M, Xu Q, Turrel-Davin F, Petit F, Hot A, Auffray C,
Bendelac N, Nicolino M, Mougin B, Thivolet C. Specific gene expression
signature associated with development of autoimmune type-I diabetes
using whole-blood microarray analysis. Genes Immun. 2010;11(3):269–78.
17. Kaldunski M, Jia S, Geoffrey R, Basken J, Prosser S, Kansra S, Mordes JP,
Lernmark A, Wang X, Hessner MJ. Identification of a serum-induced transcriptional
signature associated with type 1 diabetes in the BioBreeding rat. Diabetes.
2010;59(10):2375–85.
18. Jia S, Kaldunski M, Jailwala P, Geoffrey R, Kramer J, Wang X, Hessner MJ. Use
of transcriptional signatures induced in lymphoid and myeloid cell lines as
an inflammatory biomarker in Type 1 diabetes. Physiol Genomics. 2011;
43(11):697–709.
19. Chen YG, Mordes JP, Blankenhorn EP, Kashmiri H, Kaldunski ML, Jia S,
Geoffrey R, Wang X, Hessner MJ. Temporal induction of immunoregulatory
processes coincides with age-dependent resistance to viral-induced type 1
diabetes. Genes Immun. 2013;14:387–400.
20. Pino SC, Kruger AJ, Bortell R. The role of innate immune pathways in type 1
diabetes pathogenesis. Curr Opin Endocrinol Diab Obes. 2010;17(2):126–30.
21. Kim HS, Lee MS. Role of innate immunity in triggering and tuning of
autoimmune diabetes. Curr Mol Med. 2009;9(1):30–44.
22. Bortell R, Pino SC, Greiner DL, Zipris D, Rossini AA. Closing the circle between
the bedside and the bench: toll-like receptors in models of virally induced
diabetes. Ann N Y Acad Sci. 2008;1150:112–22.
23. Lien E, Zipris D. The role of toll-like receptor pathways in the mechanism of
type 1 diabetes. Curr Mol Med. 2009;9(1):52–68.
24. Zipris D. Innate immunity and its role in type 1 diabetes. Curr Opin Endocrinol
Diab Obes. 2008;15(4):326–31.
25. Geoffrey R, Jia S, Kwitek AE, Woodliff J, Ghosh S, Lernmark A, Wang X, Hessner
MJ. Evidence of a functional role for mast cells in the development of type 1
diabetes mellitus in the BioBreeding rat. J Immunol. 2006;177(10):7275–86.
26. Kayserova J, Vcelakova J, Stechova K, Dudkova E, Hromadkova H, Sumnik Z,
Kolouskova S, Spisek R, Sediva A. Decreased dendritic cell numbers but
increased TLR9-mediated interferon-alpha production in first degree relatives
of type 1 diabetes patients. Clin Immunol. 2014;153(1):49–55.
27. Jackson AM, Kanak MA, Grishman EK, Chaussabel D, Levy MF, Naziruddin B.
Gene expression changes in human islets exposed to type 1 diabetic serum.
Islets. 2012;4(4):312–9.
28. Moran A, et al. Interleukin-1 antagonism in type 1 diabetes of recent onset:
two multicentre, randomised, double-blind, placebo-controlled trials. Lancet.
2013;381(9881):1905–15.
29. Mandrup-Poulsen T, Pickersgill L, Donath MY. Blockade of interleukin 1 in
type 1 diabetes mellitus. Nat Rev Endocrinol. 2010;6(3):158–66.
30. Rigby MR, Ehlers MR. Targeted immune interventions for type 1 diabetes:
not as easy as it looks! Curr Opin Endocrinol Diab Obes. 2014;21(4):271–8.
31. Lord S, Greenbaum CJ. Disease modifying therapies in type 1 diabetes: where
have we been, and where are we going? Pharmacol Res. 2015;98:3–8.
32. Skyler JS. Immune therapy for treating type 1 diabetes: challenging existing
paradigms. J Clin Invest. 2015;125(1):94–6.
33. Cabrera SM, Wang X, Chen YG, Jia S, Kaldunski ML, Greenbaum CJ,
Mandrup-Poulsen T and Hessner MJ. Interleukin-1 antagonism moderates
the inflammatory state associated with Type 1 diabetes during clinical trials
conducted at disease onset. Eur J Immunol. 2016;46(4):1030–46.
34. Santos Sde S, Galatro TF, Watanabe RA, Oba-Shinjo SM, Nagahashi Marie SK,
Fujita A. CoGA: an R package to identify differentially co-expressed gene
sets by analyzing the graph spectra. PLoS One. 2015;10(8):e0135831.
35. Solé RV, Valverde S. Information theory of complex networks: on evolution
and architectural constraints. Lect Notes Phys. 2004;650:189–207.
36. Newman ME. Assortative mixing in networks. Phys Rev Lett. 2002;89(20):
208701.
37. Hirsch JE. An index to quantify an individual’s scientific research output.
Proc Natl Acad Sci U S A. 2005;102(46):16569–72.
38. Cox R, McIntyre KM, Sanchez J, Setzkorn C, Baylis M and Revie CW. Comparison
of the h-Index Scores Among Pathogens Identified as Emerging Hazards in
North America. Transbound Emerg Dis. 2016;63(1):79–9.
39. Lu L, Zhou T, Zhang QM, Stanley HE. The H-index of a network node and its
relation to degree and coreness. Nat Commun. 2016;7:10168.
40. Ruepp A, Waegele B, Lechner M, Brauner B, Dunger-Kaltenbach I, Fobo G,
Frishman G, Montrone C, Mewes HW. CORUM: the comprehensive resource
of mammalian protein complexes–2009. Nucleic Acids Res. 2010;38(Database
issue):D497–501.
41. Vinayagam A, Hu Y, Kulkarni M, Roesel C, Sopko R, Mohr SE, Perrimon N.
Protein complex-based analysis framework for high-throughput data sets.
Sci Signal. 2013;6(264):rs5.
42. Gavin AC, et al. Proteome survey reveals modularity of the yeast cell machinery.
Nature. 2006;440(7084):631–6.
43. Steck AK, Rewers MJ. Genetics of type 1 diabetes. Clin Chem. 2011;57(2):176–85.
44. Wang Q, Liu W, Ning S, Ye J, Huang T, Li Y, Wang P, Shi H, Li X. Community
of protein complexes impacts disease association. Eur J Hum Genet.
2012;20(11):1162–7.
45. Vanunu O, Magger O, Ruppin E, Shlomi T, Sharan R. Associating genes and
protein complexes with disease via network propagation. PLoS Comput
Biol. 2010;6(1):e1000641.
46. Xie Y, Ghosh S, Jailwalia P, Wang X. The Dynamic Range of Gene
Expressions Depend on Their Ontology. IEEE Comput Syst Bioinform Conf.
2004;CSB'04:580–1.
Gao et al. BMC Medical Genomics  (2017) 10:7 Page 13 of 14
47. Li J, Min R, Vizeacoumar FJ, Jin K, Xin X, Zhang Z. Exploiting the
determinants of stochastic gene expression in Saccharomyces cerevisiae for
genome-wide prediction of expression noise. Proc Natl Acad Sci U S A.
2010;107(23):10472–7.
48. Mar JC, Matigian NA, Mackay-Sim A, Mellick GD, Sue CM, Silburn PA,
McGrath JJ, Quackenbush J, Wells CA. Variance of gene expression identifies
altered network constraints in neurological disease. PLoS Genet. 2011;7(8):
e1002207.
49. Cabrera SM, Chen YG, Hagopian WA and Hessner MJ. Blood-based
signatures in type 1 diabetes. Diabetologia. 2016;59(3):414–25.
50. Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic crises in adult
patients with diabetes. Diabetes Care. 2009;32(7):1335–43.
51. Kennedy GC, German MS, Rutter WJ. The minisatellite in the diabetes
susceptibility locus IDDM2 regulates insulin transcription. Nat Genet.
1995;9(3):293–8.
52. Bennett ST, Lucassen AM, Gough SC, Powell EE, Undlien DE, Pritchard LE,
Merriman ME, Kawaguchi Y, Dronsfield MJ, Pociot F, et al. Susceptibility to
human type 1 diabetes at IDDM2 is determined by tandem repeat variation
at the insulin gene minisatellite locus. Nat Genet. 1995;9(3):284–92.
53. Maree AF, Komba M, Dyck C, Labecki M, Finegood DT, Edelstein-Keshet L.
Quantifying macrophage defects in type 1 diabetes. J Theor Biol. 2005;
233(4):533–51.
54. Wang X, He Z, Ghosh S. Investigation of the age-at-onset heterogeneity in
type 1 diabetes through mathematical modeling. Math Biosci. 2006;203(1):
79–99.
55. Bayerlova M, Jung K, Kramer F, Klemm F, Bleckmann A, Beissbarth T. Comparative
study on gene set and pathway topology-based enrichment methods. BMC
Bioinformatics. 2015;16:334.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Gao et al. BMC Medical Genomics  (2017) 10:7 Page 14 of 14
